Volume 3, Issue 2 | January 2016
Case Report | Liver

Acute Hepatitis and Pneumonitis Caused by Disseminated Bacillus Calmette-Guérin Infection

Download PDF

Khaled Dibs, MD1, Ihab Shehadeh, MD2, and Osama Abu Atta, MD3

1Department of Radiation Oncology, King Hussein Cancer Center, Amman, Jordan
2Department of Gastroenterology, King Hussein Cancer Center, Amman, Jordan
3Infectious Disease Department, King Hussein Cancer Center, Amman, Jordan

ACG Case Rep J 2016;3(2):130-132. http://dx.doi.org/10.14309/crj.2016.23. Published online: January 20, 2016.


Intravesical instillation of Bacillus Calmette-Guérin (BCG) is the treatment of choice for superficial bladder carcinoma. We report a case of disseminated BCG infection in an early stage bladder cancer patient that initially presented with hepatitis followed by pneumonitis and sepsis. A complete clinical response was achieved in 14 days with anti-mycobacterial therapy and prednisolone. Disseminated BCG is a rare treatment complication and is likely a combination of direct infection and hypersensitivity.


Bacillus Calmette-Guérin (BCG) is a live, attenuated strain of the bovine tuberculosis bacillus, Mycobacterium bovis (M. bovis). Intravesical BCG instillation for the treatment of superficial bladder cancer was first described in 1976.1 Since then, BCG therapy has become the treatment of choice for early stage transitional cell carcinoma of the bladder, with response rates of 60%–94%.2 Although the virulence of attenuated BCG is low, serious and potentially life-threatening infections can rarely occur, even in immunocompetent patients.3 Disseminated BCG infections presenting as pneumonitis or granulomatous hepatitis are extremely rare. In the largest retrospective study reported to date, dissemination occurred in only 0.7% of more than 2,000 patients.4

Case Report

A 34-year-old man with an early stage bladder cancer (stage T1) presented with a 2-day history of fatigue, night sweats, and icterus. He was previously treated with cystoscopic fulguration of the tumor, followed by 8 weeks of intravesical BCG. The last course was administered 3 weeks prior to presentation. No immediate complications or traumatic instillations were reported.

Physical examination was significant for diffuse icterus and hepatomegaly. Laboratory work-up showed an alkaline phosphatase 432 U/L, AST 70 U/L, ALT 90 U/L, total bilirubin 11.1 mg/dL, direct bilirubin 9.2 mg/dL, and prolonged PT and PTT at 22 s and 45 s, respectively. Polymerase chain reaction serum assays for cytomegalovirus and Epstein-Barr virus, and serology tests for viral hepatitis, autoimmune hepatitis, and primary biliary cirrhosis were negative. Liver ultrasound showed homogenous hepatomegaly without any lesions or biliary dilatation. Abdominal/pelvic and chest computed tomography (CT) scans were normal apart from the hepatomegaly. Liver biopsy revealed multiple, non-caseating granulomas in the portal tract and parenchyma, in addition to mild, patchy inflammation in the portal tract with eosinophilic infiltration (Figure 1). Stains for cytomegalovirus, HSV, fungi, and acid-fast bacilli were negative.


Figure 1. Liver biopsy showing (A) multiple, non-caseating granulomas in the portal tract and parenchyma, in addition to (B) mild, patchy inflammation in the portal tract with eosinophilic infiltration.

Three days after his presentation, the patient’s status deteriorated. He was found to have severe hypoxic respiratory failure and hypotension requiring mechanical ventilation and vasopressors support. Chest CT revealed bilateral, diffuse parenchymal infiltrates, consistent with pneumonitis, without hilar lymphadenopathy (Figure 2).


Figure 2. Chest CT showing bilateral, diffuse parenchymal infiltrates, consistent with pneumonitis, without hilar lymphadenopathy.

Due to the high suspicion of BCG sepsis and dissemination, triple anti-mycobacterial therapy with rifampin (600 mg daily), isoniazid (300 mg daily), and ethambutol (1200 mg daily) was initiated. A 3-day course of prednisolone was added to treat a possible hypersensitivity reaction. Bronchial lavage was negative for bacteria, fungi, and acid-fast bacilli. Four days later, the patient’s clinical status improved significantly and he was successfully extubated. In 2 weeks, liver enzymes and function tests returned to normal ranges. Fungal cultures from the liver and lungs were negative after 6 weeks. Anti-mycobacterial therapy was continued for 12 months.


BCG is an attenuated strain of the tuberculosis bacillus M. bovis. BCG induces an intense, localized inflammatory response upon instillation into the bladder. Its therapeutic mechanism of action is thought to involve the ingestion of viable mycobacteria by urothelial cells. This triggers a cytokine-mediated inflammatory response that results in the destruction of tumor cells. Since its introduction in the 1970s, intravesical BCG treatment has been an effective adjunctive treatment option of superficial bladder cancer, with a favorable safety profile and typically localized and self-limited side effects.1 However, complications like granulomatous involvement of lung, liver, and bone marrow can rarely occur.4

Acid-fast bacilli staining and organism cultures may fail to identify M. bovis, despite a high clinical suspicion of BCG infection.5 The fastidious growth nature of BCG in cultures and the doubling time of 24 to 48 hours might contribute to the difficulty of its isolation. Hepatic and pulmonary involvement have been reported as a part of BCG dissemination; however, the occurrence of hypotension and BCG sepsis has been only reported twice in the literature.6,7

The mechanism of infectious complications caused by BCG immunotherapy is debatable. It can represent either a direct active infection or a hypersensitivity reaction.8 Leebeek et al demonstrated the presence of M. bovis in liver tissues by PCR amplification, thus supporting the concept of hematogenous dissemination and direct tissue damage.5,9 On the other hand, the response to glucocorticoids when added to the anti-tuberculous agents, the striking eosinophilic infiltration of liver tissues, the absence of necrosis in the granulomas, and the absence of recoverable organisms support the hypersensitivity reaction.5,10 Our case highlights the limitations of acid-fast bacilli and mycobacterium culture.

The mainstay therapy for severe systemic BCG infections is a multi-drug combination of isoniazid, rifampin, and ethambutol for at least 6 months. Pyrazinamide is not usually recommended due to high resistance. Cautious addition of glucocorticoids in patients with BCG sepsis is recommended if hypersensitivity is believed to be part of the pathogenesis.8


Author contributions: K. Dibs wrote the manuscript and is the article guarantor. O. Abu Atta and I. Shehadeh reviewed the manuscript.

Financial disclosure: None to report.

Informed consent was obtained for this case report.

Correspondence: Khaled Dibs, KHCC, Queen Rania Abdullah St, Amman 11191, Jordan (kdibs@khcc.jo).

Received April 29, 2015; Accepted October 6, 2015


  1. Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol. 1976;116(2):180. PubMed
  2. Oosterlinck W, van der Meijden A, Sylvester R, et al. Guidelines on TaT1 (non-muscle invasive) bladder cancer. European Association of Urology Guidelines. Arnhem (The Netherlands): European Association of Urology. 2006:1–17.
  3. Koga H, Kuroda M, Kudo S, et al. Adverse drug reactions of intravesical Bacillus Calmette-Guerin instillation and risk factors of the development of adverse drug reactions in superficial cancer and carcinoma in situ of the bladder. Int J Urol. 2005;12(2):145–51. Article | PubMed
  4. Lamm DL, Van der Merjden PM, Morales A, et al. Incidence and treatment of complications Bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol. 1992;147(3):596-600. PubMed
  5. Scully R, Mark EJ, Mcneely WF, Ebeling SH. Case records of the Massachusetts General Hospital, Case 29-1998. A 57-year-old man with fever and jaundice after intravesical instillation of Bacille Calmette-Guérin for bladder cancer. N Engl J Med. 1998;339(12):831. PubMed
  6. Garyfallou GT. Mycobacterial sepsis following intravesical instillation of Bacillus Calmette-Guérin. Acad Emerg Med. 1996;3(2):157–60. PubMed
  7. Torriani R, Zimmermann A, Morell A. BCG sepsis as a fatal complication of BCG vaccination [in German]. Schweiz Med Wochenschr. 1979;109(19):708–14. PubMed
  8. Proctor DD, Chopra S, Rubenstein SC, et al. Mycobacteremia and granulomatous hepatitis following initial intravesical Bacillus Calmette-Guerin instillation for bladder cancer. Am J Gastroenterol. 1993;88(7):1112–1115. PubMed
  9. Leebeek FW, Ouwendijk RJ, Kolk AH, et al. Granulomatous hepatitis caused by Bacillus Calmette-Guerin. Gut. 1996;38(4):616–8. Article | PubMed
  10. DeHaven JI, Traynellis C, Riggs DR, et al. Antibiotic and steroid therapy of massive systemic Bacillus Calmette-Guerin toxicity. J Urol. 1992;147(3):738–42. PubMed

CC Icon

© 2016 Dibs et al. This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0.